
Antibody Drug Conjugates (ADC)
Description
Global Antibody Drug Conjugates (ADC) Market to Reach US$23.2 Billion by 2030
The global market for Antibody Drug Conjugates (ADC) estimated at US$10.8 Billion in the year 2024, is expected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Breast Cancer End-Use, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Blood Cancer End-Use segment is estimated at 13.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 18.4% CAGR
The Antibody Drug Conjugates (ADC) market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 11.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.8% CAGR.
Global Antibody Drug Conjugates (ADC) Market - Key Trends and Drivers Summarized
What Are Antibody Drug Conjugates and How Are They Revolutionizing Cancer Treatment?
Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas, and solid tumors.
How Is the ADC Market Segmented and What Are the Key Applications?
Technologically, the market is divided into types of linkers and payloads used, which are critical components in ensuring the drug’s stability and efficacy. In terms of application, breast cancer currently dominates the ADC market, given the high success rate of treatments like Kadcyla and Enhertu. Other target indications include hematologic malignancies and solid tumors, with ongoing clinical trials aiming to expand the use of ADCs to more cancer types. End-users primarily include hospitals, oncology clinics, and cancer research institutes, where ADCs are administered as part of comprehensive cancer treatment regimens. North America leads the market due to its advanced healthcare infrastructure and high investment in oncology research, while Europe and Asia-Pacific are emerging as key regions due to increasing healthcare expenditures and cancer prevalence.
How Are Technological Innovations Impacting the ADC Market?
Technological advancements are playing a pivotal role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug release at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also enhancing the potency of ADCs, making them more effective against drug-resistant cancer cells. Moreover, ongoing research in identifying new cancer biomarkers is expanding the potential applications of ADCs beyond current use cases, allowing for the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies like the FDA are also expediting approvals for new ADC therapies, recognizing their potential to transform cancer treatment.
What Factors Are Driving the Growth in the Antibody Drug Conjugates Market?
The growth in the Antibody Drug Conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. The advancements in linker technologies and payload delivery systems have enhanced the efficacy and safety profile of ADCs, contributing to their growing adoption in oncology. Furthermore, the rise in personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is propelling the development of ADCs. Clinical success and the approval of leading ADC products have spurred further investment in R&D, expanding the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy are further driving market growth.
SCOPE OF STUDY:
The report analyzes the Antibody Drug Conjugates (ADC) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
End-Use (Breast Cancer End-Use, Blood Cancer End-Use, Other End-Uses)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Select Competitors (Total 52 Featured) -
- ADC Therapeutics SA
- Astellas Pharma, Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co., Ltd.
- Enzo Biochem, Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GSK Plc
- ImmunoGen, Inc.
- MabPlex International
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Economic Frontiers: Trends, Trials & Transformations
- Antibody Drug Conjugates (ADC) – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Cancer Drives Demand for Targeted Therapeutic Solutions
- Technological Advancements in Biopharmaceuticals Propel Growth of ADC Market
- Expansion of Precision Medicine Strengthens Business Case for Antibody Drug Conjugates
- Rising Focus on Immuno-Oncology Fuels Innovation in ADC Development
- Advancements in Targeted Drug Delivery Systems Propel Growth of ADC Therapies
- Expanding Use of ADCs in Hematologic Malignancies Drives Market Demand
- Rising Interest in Combination Therapies Strengthens Adoption of ADCs in Cancer Treatment
- Increasing Focus on Personalized Medicine Expands Addressable Market for ADC-Based Therapies
- Growing Awareness of Precision Therapeutics Sustains Demand for Targeted Cancer Therapies
- Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
- Rising Prevalence of Chronic Diseases Beyond Cancer Expands Applications of ADCs
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Antibody Drug Conjugates (ADC) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Breast Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Blood Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: USA 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: Canada 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- JAPAN
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: Japan 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- CHINA
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: China Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: China 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- EUROPE
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: Europe 15-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Europe 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- FRANCE
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: France Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: France 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- GERMANY
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Germany 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Italy 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: UK 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 44: Spain Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Spain Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Spain 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 47: Russia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Russia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Russia 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Rest of Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Rest of Europe 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- AUSTRALIA
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 59: Australia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Australia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Australia 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- INDIA
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 62: India Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: India Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: India 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 65: South Korea Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: South Korea Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: South Korea 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Rest of Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Rest of Asia-Pacific 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 71: Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 72: Latin America Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Latin America 15-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 74: Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Latin America Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Latin America 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 77: Argentina Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Argentina Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Argentina 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 80: Brazil Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Brazil Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Brazil 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 83: Mexico Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Mexico Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Mexico 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Latin America Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Rest of Latin America 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 89: Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 90: Middle East Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Middle East 15-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 92: Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Middle East Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Middle East 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- IRAN
- TABLE 95: Iran Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Iran Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Iran 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 98: Israel Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Israel Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Israel 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Saudi Arabia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Saudi Arabia 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 104: UAE Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: UAE Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: UAE 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Rest of Middle East Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Rest of Middle East 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- AFRICA
- Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 110: Africa Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Africa Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Africa 15-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates